06/2018 Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension

05/2018 Denovo Biopharma to Participate in Jefferies 2018 Global Healthcare Conference

05/2018 Denovo Biopharma to Participate at Morgan Stanley 4th Annual China Summit

04/2018 First Patient Dosed In Pivotal Biomarker-Guided Phase 3 Study Of First Line Therapy With DB102 (enzastaurin) + R-CHOP In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

01/2018 San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO

10/2017 Denovo Biopharma Receives FDA's Permission to Proceed a Phase 3 Clinical Trial with DB102 (Enzastaurin) In the First Line Treatment of High Risk DLBCL

4/2017 Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI

2/2017 Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma

12/2015 Denovo Biopharma attends 54th Annual Meeting of American College of Neuropsychopharmacology

12/2015 Denovo Biopharma attends 2015 American Society of Hematology Annual Meeting

11/2015 Denovo Biopharma attends 2015 Bio-Europe

9/2015 Denovo Biopharma attends 2015 Biopharma America

6/2015 Denovo Biopharma presents at 6th international translational medicine forum

5/2015 Denovo Biopharma completes a series A financing led by a group of leading healthcare investors

4/2015 Denovo Biopharma presents at personalized medicine forum hosted by Huachuang Securities

3/3/2015 Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine

11/03/2014 Personalized Medicine Pioneer K. Peter Hirth, Ph.D., Joins Denovo Biopharma Advisor Board

9/16/2014 Denovo Biopharma acquires late-stage oncology drug from Lilly for development as personalized medicine

7/1/2014 Denovo Biomarkers is transitioning into Denovo Biopharma to better reflect the business focus of the company

6/26/2014 At BIO 2014, Denovo Biomarkers CSO Dr. Wen Luo will present at Personalized Medicine and Diagnosic Forum, San Diego, CA, USA

2/16/2014 Denovo Biomarkers has been selected for the 2013 United States Excellence Award amongst all its peers and competitors by the US Institute for Excellence in Commerce (USIEC)

2/10/2014 Denovo Biomarkers Attends 16th Annual BIO CEO & Investor Conference. Venue: The Waldorf Astoria New York, New Yor, NY, USA

1/13/2014 Denovo Biomarkers Attends 2014 Annual OneMedForum at San Francisco. Venue: Westin San Francisco, CA, USA

1/11/2014 Denovo Biomarkers Attends 2014 East/West CEO Conference at San Francisco. Venue: Four Seasons Hotel, San Francisco, CA, USA

11/16/2013 Denovo Biomarkers Presents at 5th Shanghai International Forum of Regional & Targeting Therapies 2013. Venue: Everbright Hotel, Shanghai, China

11/15/2013 Denovo Biomarkers Presents at IDDST 2013 - BIT's 11th Annual Congress of Int‘l Drug Discovery Science & Technology, Therapy & EXPO. Venue: Haikou, Hainan, China

11/14/2013 Denovo Biomarkers Presents at Global Clinical Development Summit - China Trial. Venue: Sofitel Wanda Plaza Hotel, Beijing, China

11/12 -13/2013 Denovo Biomarkers Attends BIO China 2013. Venue: National Convention Center, Beijing, China

11/12/2013 Denovo Biomarkers Attends BIO Europe 2013. Venue: National Confences Center, Vienna, Austria

10/28-30/2013 Denovo Biomarkers Presents at 2013 Bionetwork. Venue: The Ritz-Carlton, Laguna Niguel, California, United States

09/17-19/2013 Denovo Biomarkers Attends BioPharm America 2013. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States

05/10/2013 Denovo Biomarkers Announces a Partnership with The ALS Emergency Treatment Fund to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments.

03/12/2013 Denovo Biomarkers President Xiangming Fang Presents at 7th Annual BIO-Europe Spring Conference 2013. Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, Barcelona, Spain.

02/26/2013 Denovo Biomarkers Chief Operating Officer Michael Haller Presents at 11th Annual BioPartnering North America. Venue: Vancouver Convention Centre, Vancouver, British Columbia, Canada

02/12/2013 Denovo Biomarkers Chief Scientific Officer Wen Luo Presents at CHI's Molecular Diagnostics Partnering Forum. Venue: Moscone Convention Center, San Francisco, California, United States

01/07/2013 Denovo Biomarkers Chief Business Officer Robert Little Presents at EBD Group AG's Biotech showcase 2013. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States